Trials / Completed
CompletedNCT01775124
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Intravitreal injections of 0.5 mg Ranibizumab |
Timeline
- Start date
- 2013-02-22
- Primary completion
- 2015-11-23
- Completion
- 2015-11-23
- First posted
- 2013-01-24
- Last updated
- 2019-09-04
- Results posted
- 2018-02-12
Locations
23 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01775124. Inclusion in this directory is not an endorsement.